CommercialCoverageMedium impact
08.01.18i, Vedolizumab (Entyvio®) for Injection for Intravenous Use
Independence Blue Cross·Gastroenterology, Pharmacy·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the Vedolizumab (Entyvio®) policy effective 11/26/2025. Without access to the full policy text content, specific changes cannot be determined. The billing team must obtain and review the complete policy document to identify whether coverage criteria, prior authorization requirements, billing codes, or reimbursement terms have changed compared to the previous version.
Action Required
By 11/26/2025: Billing team must obtain the complete policy text from the source URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-18i) and compare it to the previous policy version. Identify specific changes to prior authorization requirements, coverage criteria, or applicable HCPCS codes for Vedolizumab administration. Update billing system rules, provider alerts, and patient financial counseling accordingly. Document all changes in the compliance file. Failure to implement changes by the effective date may result in claim denials or improper reimbursement.